oncgnostics at EUROGIN 2022
The EUROGIN is THE event for our current application areas and most of the experts were in Düsseldorf. So were we! With four presentations oncgnostics participated in the scientific discourse at the International multidisciplinary HPV Congress.
The congress was again a great opportunity for us to make new contacts, maintain existing partnerships and exchange ideas about possible new collaborations.
oncgnostics participates in the scientific discourse
Oncgnostics submitted four presentations in the run-up to EUROGIN 2022 and all four were accepted. After a long period of digital-only events, our team was looking forward to receiving direct feedback and exchanging ideas with international colleagues:
Dr Alfred Hansel, Managing Director:
“After two long years, we are present again, meeting competitors, cooperation partners, clinicians and scientists. We present our data, discuss them at our booth with all interested parties, also have conversations with chance meetings again.’
Dr Martina Schmitz, Managing Director:
“I had the impression that all participants were simply happy to be able to exchange information about the latest studies and results live again after 2 years of the pandemic. GynTect-PRO talk had a good response and our booth enjoyed great interest.”
Anna-Bawany Hums, molecular biologist:
“EUROGIN in Düsseldorf has already been worthwhile, as it is the first face-to-face event for me after two years. It’s fun to come into direct contact with interested people at the booth again, to meet existing cooperation partners and to exchange ideas about new projects.”
Carolin Hoyer, biotechnologist:
“EUROGIN was my first big conference and I had the opportunity to present my Master’s thesis there, listening to interesting talks and make friendly contacts.”
Contributions of oncgnostics GmbH at EUROGIN 2022
If you were not on site or would like to read the contents, you can download the respective short summaries of the presentations:
- Dr Martina Schmitz: GynTect® DNA methylation marker – longitudinal observational study in patients with CIN2/3. Results from the GynTect-PRO trial
- Dr Alfred Hansel: Assessment of DNA methylation markers for the detection of VIN, VAIN and vulva or vagina carcinoma
- Anna-Bawany Hums: Clarification testing/triage of women tested HPV DNA-positive in cervical cancer screening using a DNA methylation marker-based test as well as an HPV mRNA test
- Carolin Hoyer: Promising epigenetic biomarkers for improved detection of head and neck cancer in non-invasive specimen